SCHEDULE: Deerfield Funds Significantly Reduce Stake in ARS Pharmaceuticals

Deerfield Private Design Funds have substantially decreased their beneficial ownership in ARS Pharmaceuticals, Inc. through a series of open market sales in July 2025.

Summary

• Deerfield Management Company and its affiliated funds, Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., filed an Amendment No. 4 to their Schedule 13D regarding ARS Pharmaceuticals, Inc.
• The filing details open market sales of ARS Pharmaceuticals common stock by the Deerfield Funds between July 10, 2025, and July 21, 2025.
• A total of 1,090,971 shares were sold across multiple transactions during this period.
• Weighted average sale prices for most transactions ranged from $18.00 to $18.12 per share, with a notable exception on July 18, 2025, where 113,380 shares were sold at a weighted average price of $8.13 per share, despite a reported price range of $18.00 $18.54 for that day.
• Following these transactions, the aggregate beneficial ownership of ARS Pharmaceuticals common stock by Deerfield Management Company and James E. Flynn stands at 8,633,537 shares, representing 8.79% of the outstanding common stock.
• Individual beneficial ownership for Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. is approximately 4.40% each.
• The percentage beneficial ownership is calculated based on 98,213,561 shares of Common Stock outstanding as of May 12, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative as a major institutional investor has significantly reduced its stake, which can be interpreted as a loss of confidence or a strategic exit, potentially putting downward pressure on the stock price.

Negatives

• A significant reduction in beneficial ownership by a major institutional investor, Deerfield Funds, which could signal a diminished outlook or strategic divestment.
• The sale of over 1 million shares by a large holder may create downward pressure on the stock price due to increased supply in the market.
• The reported weighted average sale price of $8.13 for a portion of the shares sold on July 18, 2025, is substantially lower than other reported sale prices, potentially indicating a discounted sale or specific market conditions that are unfavorable.

Risks

• Increased selling pressure on ARS Pharmaceuticals' common stock due to the large volume of shares divested by a significant institutional holder.
• Potential negative market perception or loss of investor confidence stemming from a major investor reducing its stake.
• Uncertainty regarding the underlying reasons for Deerfield Funds' substantial reduction in ownership, which could imply a change in their investment thesis or concerns about the company's future performance.

Future Outlook

NA

Industry Context

This filing reflects a significant portfolio adjustment by a major healthcare-focused investment firm, Deerfield Management, in a biotechnology or pharmaceutical company. Such reductions by large institutional investors can sometimes signal a shift in sector-specific investment strategies or a re-evaluation of individual company prospects, potentially influencing broader market sentiment within the biotech/pharma industry.

Related Party Transactions

• Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. (the 'Deerfield Funds') are investment vehicles managed by Deerfield Management Company, L.P.
• James E. Flynn is the managing member of the general partner of Deerfield Mgmt IV, Deerfield Mgmt III, and Deerfield Management, establishing a direct relationship with the selling entities.
• The transactions detailed in the filing represent sales of common stock by these affiliated Deerfield entities.

Stakeholder Impact

• Shareholders: The reduction in ownership by a significant institutional investor may lead to concerns about the company's future prospects and could contribute to downward pressure on the stock price.
• Potential Investors: The filing provides transparency regarding a major investor's reduced position, which could influence investment decisions.

Key Dates

Recommendation

The significant reduction in stake by a major institutional investor like Deerfield Management, selling over 1 million shares, signals a potential loss of confidence or a strategic divestment. This action typically exerts downward pressure on the stock price and may indicate that the investor sees limited upside or increased risk. The notable drop in weighted average price for some sales further reinforces a negative outlook, suggesting that the market may be absorbing these shares at lower valuations. Investors should consider this as a strong signal to re-evaluate their position and potentially reduce exposure.

Keywords

ARS Pharmaceuticals, Deerfield Management, Schedule 13D/A, Stock Sales, Beneficial Ownership, Institutional Investor, Common Stock, Equity, Biotechnology, Pharmaceuticals